United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Innoviva

Moderna

Sanofi

Gilead Sciences

As drug makers race to develop vaccine to fight coronavirus, we shortlist five stocks that are poised to grow on progress in clinical trials.

5 Stocks to Buy as Coronavirus Vaccine in Human Trails Ramp Up

Amazon

With the U.S. importing mass quantities of personal protective equipment, medical gear, COVID-19 tests, and more, a lot of substandard and outright counterfeit gear is landing on our shores.

U.S. Customs Agency Enlists Amazon, Pfizer, 3M in Fight Against Counterfeit Coronavirus Products

Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) said Tuesday that a Phase 1/2 trial of their coronavirus vaccine candidates has commenced in the U.S.

Pfizer Begins Human Testing Of Coronavirus Vaccine In US, Michigan Among Manufacturing Centers

BioNTech SE

Clinical trials of their experimental vaccine to prevent COVID-19 started in Germany last month.

Pfizer and BioNTech Begin U.S. Trials of SARS-CoV-2 Vaccine Candidate

Agency says partnership with big companies will curtail imports of suspect masks and test kits.

The Wall Street Journal: ICE partners with Amazon, 3M and Pfizer to identify counterfeit coronavirus gear

Pfizer and BioNTech dosed the first patients in a study of their coronavirus vaccine on Tuesday; shares of both drugmakers rose. Test makers Chembio and GenMark also popped.

Covid Report: Pfizer Begins Vaccine Study; Test Makers Surge On Demand

BioNTech SE (NASDAQ: BNTX) and Pfizer Inc. (NYSE: PFE) stocks each made a handy gain on Monday after the companies announced the beginning of human trials for a COVID-19 vaccine.

BioNTech and Pfizer Kick Off Human Trials for COVID-19 Vaccine

Catalent

GlaxoSmithKline

Johnson & Johnson

Vir Biotechnology

Around 70 companies are working on coronavirus treatments. Here are a few with the most promise.

Finding a Coronavirus Cure: 5 Companies Making Moves

Four vaccines are being tested at once with the goal of shortening development time.

Pfizer Launches U.S. Human Trial Of Coronavirus Vaccine

Shares of BioNTech SE BNTX, +1.48% rallied 4.8% in premarket trading, after the immunotherapy company and Pfizer Inc.

BioNTech, Pfizer stocks rally after first participants in U.S. trial of COVID-19 vaccine were dosed

Pfizer and BioNTech said on Tuesday they have begun delivering doses of their experimental coronavirus vaccines for initial human testing in the United States.

Pfizer, BioNTech are set to begin US coronavirus vaccine trial

The U.S.-based company, which is working alongside German drugmaker BioNTech, said the first human participants in the United States have been dosed with the potential vaccine, BNT162.

Pfizer begins human testing for experimental coronavirus vaccine in the US

One of the Dogs of the Dow for 2020, Pfizer beat estimates on April 28 but ended last week below its monthly pivot for May at $38.23.

Pfizer Beats Estimates, but Stock Is Below Risky Level

Chevron

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Exxon Mobil

A scorecard of Chevron, IBM and other Dogs of the Dow.

How Have The ‘Dogs Of The Dow’ Been Performing?

They're off to a fast start, but the companies still have a long ways to go.

Pfizer and BioNTech Complete Dosing of First Group in Coronavirus Vaccine Trial

Ken Fisher's ( Trades ,  Portfolio ) Fisher Asset Management, LLC sold shares of the following stocks during the first quarter of 2020.

Fisher Asset Management Cuts Pfizer, Johnson & Johnson

MAINZ, Germany and NEW YORK, April  29, 2020  (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE) have announced that the first cohort of BioNTech’s Phase 1/2 clinical trial has been dosed. Twelve study participants were dosed with vaccine candidate BNT162 in Germany since dosing began on April 23, 2020. The trial is the first clinical trial of a COVID-19 vaccine candidate in Germany. Pfizer and BioNTech plan to initiate trials for BNT162 in the United States upon regulatory approval, which is expected shortly.

BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany

Pfizer Inc. (NYSE: PFE) chief executive officer Albert Bourla on Tuesday said the clinical trials for its novel coronavirus (COVID-19) vaccine are expected to start next week in the United States, pending approval from health regulators.

Pfizer Says Coronavirus Vaccine Could Be Available By Fall, US Clinical Trials To Begin Next Week

Pfizer Inc. (PFE) CEO Albert Bourla on Q1 2020 Results - Earnings Call Transcript

Southwest Airlines

Harley-Davidson

PepsiCo

PepsiCo, Harley-Davidson, Pfizer and Southwest Airlines were our top stock trades. That said, here's a look at their post-earnings setups.

4 Top Stock Trades for Wednesday: HOG, LUV, PEP, PFE

Merck

Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc.

Why Pfizer and Merck Earnings Are Slowing the Dow

There was plenty of good news buried beneath the big drugmaker's negative headline numbers.

Pfizer's Sales Sank 8% in Q1. Here's Why Some Investors Liked the Results Anyway.

Pfizer (PFE) beats estimates for earnings. While the coronavirus pandemic hurts sales of some Pfizer medicines, it benefited sales of others, resulting in a net positive benefit on total sales.

Pfizer (PFE) Q1 Earnings Top, Biopharma Gains From Coronavirus

Pfizer (NYSE: PFE) stock declined 4% from $39 in the beginning of this year to $37 as of April 24, compared to over a 10% decline for the broader S&P 500. While Pfizer stock has outperformed the broader markets, we believe there is close to 20% upside potential from the current levels.

Buy, Sell, Or Hold Pfizer At $37?

Caterpillar

Alphabet

Starbucks

Normally you see a quiet market on the days of a Fed meeting, but today could be an exception because the Fed has done so much already and there’s so many earnings reports out today. Crude remains under pressure but off its worst overnight lows, and volatility continues to ease.

News for Pfizer Stock (PFE)